Treatment of amyotrophic lateral sclerosis (ALS) with ibudilast
Compositions and methods for treating progressive neurodegenerative diseases, and their associated symptoms by administration of ibudilast (3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine).
1. A method of treating a patient diagnosed with amyotrophic lateral sclerosis (ALS) comprising administering to said patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof ranging between 1-240 mg/day.
2. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least six months.
3. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least one year.
4. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered for at least two years.
5. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered at least once daily.
6. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered orally.
7. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered in an amount of 30 mg to 240 mg daily.
8. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered in an amount of 30 mg to 120 mg daily.
9. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered in an amount of 1 mg to 120 mg daily.
10. The method of claim 1 in which the ibudilast or pharmaceutically acceptable salt thereof is administered in a total daily dosage amount selected from the group consisting of 30 mg/day, 60 mg/day, 90 mg/day and 120 mg/day.
11. A method of treating a patient diagnosed with amyotrophic lateral sclerosis (ALS) comprising administering to said patient a therapeutically effective amount of ibudilast or a pharmaceutically acceptable salt thereof ranging between about 0.1 and 200 mg/day.
12. The method of claim 11 in which the ibudilast or pharmaceutically acceptable salt thereof is administered in a total daily dosage amount selected from the group consisting of 30 mg/day, 60 mg/day, 90 mg/day and 120 mg/day.